YB
The startup operates a biotechnology research platform focused on developing xeno-free vascular endothelial progenitor cell therapies for diabetic foot ulcers and ischemic vascular diseases. This approach aims to provide effective treatment options for patients suffering from renal vascular and stroke-related complications.
Updated 3 months ago
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup operates a biotechnology research platform focused on developing xeno-free vascular endothelial progenitor cell therapies for diabetic foot ulcers and ischemic vascular diseases. This approach aims to provide effective treatment options for patients suffering from renal vascular and stroke-related complications.